Galactose treatment in focal segmental glomerulosclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020
   Guideline
2. The glomerular permeability factors in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016
   Review
3. Recurrence and Treatment after Renal Transplantation in Children with FSGS.BioMed research international · 2016
   Review
4. Nephrotic syndrome: what's new, what's hot?Korean journal of pediatrics · 2015
   Review
5. Response: galactose treatment in focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2014
   Article

Corrections and comments

• Commented on by
  Response: galactose treatment in focal segmental glomerulosclerosis.2014
• Comment on
  Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as